{"changes":[],"country":"US","description":"Anagram Therapeutics develops oral enzyme replacement therapies for rare malabsorption and nutrient metabolism disorders. Its lead candidate ANG003 is in Phase 2 trials for cystic fibrosis and exocrine pancreatic insufficiency in infants, children, and adults. Proprietary enzyme stabilization technology extends activity through the GI tract where competitors degrade.","domain":"anagramtx.com","employees":null,"founded":2017,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"biotech","investors":[],"lat":42.283639,"lng":-71.346996,"location":"Natick, MA","name":"Anagram Therapeutics","rounds":[{"amountQuarantined":false,"amountUsd":250000000,"currency":"USD","date":"2026-05-08","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-14","status":"attributed","url":null},"status":"attributed","type":"series-c","url":null}],"slug":"anagramtx-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-14","status":"attributed","url":null},{"fact":"existence","publisher":"anagramtx.com","retrievedAt":"2026-05-14","status":"self-reported","url":"https://anagramtx.com"},{"fact":"description","publisher":"anagramtx.com","retrievedAt":"2026-05-14","status":"self-reported","url":"https://anagramtx.com"}],"stage":"series-b+","techStack":["Nginx","Bootstrap 5.3.2","Google Analytics","Google Tag Manager","jQuery CDN","jsDelivr","ExpressionEngine","DoubleClick Floodlight","CodeIgniter","WordPress","PHP","MySQL"],"totalRaisedUsd":285000000,"updatedAt":"2026-05-14"}